H1N1 Vaccine Market Overview
H1N1 Vaccine Market size is forecast to reach $2.3 billion by 2025, growing at a CAGR of 4.51% during the forecast period 2020-2025. H1N1 influenza virus or swine H1N1 virus is a causative agent of infectious disease caused in human beings known as H1N1 or commonly referred to as swine flu. The H1N1 virus mainly affects the respiratory system including the nose, lungs, and throat of the infected person. Increasing incidences of epidemic H1N1 infection and declining immunity among the geriatric population are the major factors driving the growth of the market. Innovation in vaccine manufacturing to obtain universally acceptable vaccine for the H1N1 virus and increased awareness on H1N1 influenza is set to further enhance the overall market demand for H1N1 Vaccine Market during the forecast period 2020-2025.
North America dominated the H1N1 Vaccine Market in 2019 owing to the increasing initiatives for the prevention of H1N1 infection and technological advancements in the vaccine’s presence of well-established healthcare infrastructure. The H1N1 Vaccine Market scope for different regions will be provided in the final report.
Rising vaccine manufacturing technologies and improved profitability for the industry are likely to aid in the market growth of the H1N1 Vaccine Market.
Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the H1N1 Vaccine Market report.
Stringent regulatory rules and the absence of experienced medical professionals is poised to create hurdles for the H1N1 Vaccine Market.
H1N1 Vaccine Market Segment Analysis – By Vaccine Type
The Intramuscular held the largest share in the H1N1 Vaccine Market in 2019 and is estimated to grow at a CAGR of 5.19% during the forecast period 2020-2025. An intramuscular injection is a procedure used to deliver a medication deep into the muscles which allow the medication to be absorbed into the bloodstream quickly. Intramuscular injections are absorbed faster than subcutaneous injections owing to the fact that muscles have a greater blood supply than the tissue present under the skin. Moreover, muscle tissue can also hold a larger volume of medication than subcutaneous tissue. Intramuscular injections are a common practice in modern medicine. They’re used to deliver drugs and vaccines. Several drugs and almost all injectable vaccines are delivered this way. Intramuscular injections are used when other types of delivery methods aren’t recommended. Intramuscular injections are absorbed faster than subcutaneous injections since muscle tissue has a greater blood supply than the tissue just under the skin. Muscle tissue can also hold a larger volume of medication than subcutaneous tissue. Oral and Intramuscular vaccination has been considered to date as the ultimate way, but the nasal route offers advantages such as ease of self-administration and induction of mucosal as well as systemic immunity. Both liquid and dry powder formulations can be given via the intranasal route. Great consideration has to be given while selecting a suitable device for nasal administration since the volume delivered is very low. Several devices are available based on the number of doses to be administered and the type of dosage formulation Intramuscular is set to be the highest growing segment and is estimated to register the highest CAGR during the forecast period 2020-2025.
H1N1 Vaccine Market Segment Analysis – By Geography
North America dominated the H1N1 Vaccine Market in 2019 with a share of more than 38.97%, followed by the Asia Pacific owing to increasing awareness among the masses about the diseases coupled with growing government initiatives and programs to raise awareness among people about various infectious diseases.
However, Asia Pacific is estimated to grow at a higher CAGR during the forecast period 2020-2025 owing to the discovery of new vaccines with greater efficiency, and advancements in the field of biomedical science. Increasing awareness among people about preventable diseases, the government launched programs to eradicate such infectious diseases and their causes, low wages to be paid to the workers, availability of a large talent pool and skilled personnel and less stringent environment and health safety regulations is also increasing the growth of the H1N1 vaccine market in this region.
H1N1 Vaccine Market Drivers
Increasing incidences of epidemic H1N1 infection and declining immunity among the geriatric population
Increasing incidences of epidemic H1N1 infection and declining immunity among the geriatric population is increasing the growth of the H1N1 Vaccine Market. Flu virus known as H1N1 is a combination of viruses from pigs, birds, and humans. H1N1 caused respiratory infection in humans that was commonly referred to as swine flu. Influenza virus causes acute upper and lower respiratory infections and is the most likely, among known pathogens, to cause a large epidemic in humans. The influenza virus mutates rapidly, enabling it to evade natural and vaccine-induced immunity. Furthermore, influenza viruses can cross from animals to humans, generating novel, potentially pandemic strains. Currently, available influenza vaccines induce a strain-specific response and might be ineffective against new influenza viruses. The difficulty in predicting circulating strains has frequently resulted in a mismatch between the annual vaccine and circulating viruses. Influenza viruses circulate globally and affect all age groups. Vaccines are the best tools available for preventing influenza illness. Thus, increasing the growth of the H1N1 Vaccine Market during the forecast period 2020-2025.
Innovation in vaccine manufacturing to obtain the universally acceptable vaccine for H1N1 virus and increased awareness on H1N1 influenza
Innovation in vaccine manufacturing to obtain the universally acceptable vaccine for the H1N1 virus and increased awareness of H1N1 influenza is increasing the growth of the H1N1 Vaccine Market Several new technologies and associated tools have the potential to revolutionize influenza surveillance and response activities. These include the increasingly routine use of whole-genome next-generation sequencing and other high-throughput approaches. Such approaches could not only become key elements in outbreak investigations but could drive a new surveillance paradigm. However, despite the advances made, significant challenges need to be addressed before next-generation technologies become routine, particularly in low-resource settings. Strengthening the vaccine virus selection process additionally requires the continuation of initiatives to improve the timeliness and representativeness of influenza viruses. Emerging approaches and techniques such as synthetic genomics, systems genetics, systems biology, and mathematical modelling are capable of generating potentially huge volumes of highly complex and diverse datasets. Growing awareness of influenza as an important global public health issue has been coupled to ever-increasing demands from the global community for more equitable access to effective and affordable influenza vaccines. The current influenza vaccine landscape continues to be dominated by egg-based inactivated and live attenuated vaccines, with a small number of cell-based and recombinant vaccines. Thus, increasing the growth of the H1N1 Vaccine Market during the forecast period 2020-2025.
H1N1 Vaccine Market Challenges
Stringent regulatory rules and the absence of experienced medical professionals
Some of the factors that can impede the growth of the H1N1 Vaccine Market are stringent regulatory rules and the absence of experienced medical professionals. The high capital requirement, ample production to meet the population demand is set to create hurdles for the H1N1 vaccine market.
H1N1 Vaccine Industry Outlook
Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the H1N1 Vaccine Market. In 2019, the H1N1 Vaccine Market share is consolidated by the top ten players present in the market. H1N1 Vaccine, the top 10 companies are Abbott Laboratories, Pfizer, CPL Biologicals, Zydus Cadila, CSL Limited, Mitsubishi Tanabe Pharma Corporation, Glaxosmith, Commonwealth Serum Laboratories, Sinobac, and Astra Zeneca Plc. among others.
In April 2016, Abbott Laboratories acquired St. Jude Medical for $25Bn.